Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. It operates in the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. The company is headquartered in Hackensack. New Jersey. Show more

Location: 2 University Plaza, Hackensack, NJ, 07601, United States | Website: https://www.protalix.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

112.2M

52 Wk Range

$0.82 - $3.10

Previous Close

$1.48

Open

$1.46

Volume

1,007,451

Day Range

$1.41 - $1.47

Enterprise Value

88.31M

Cash

34.74M

Avg Qtr Burn

-143K

Insider Ownership

10.39%

Institutional Own.

10.78%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ELFABRIO (Pegunigalsidase alfa )(PRX-102) Details
Genetic disorder, Rare genetic disease

Approved

Quarterly sales

Elelyso® (taliglucerase alpha) Details
Genetic disorder, Rare genetic disease

Approved

Quarterly sales

PRX-115 Details
Chronic refractory gout

Phase 2

Initiation

Alidornase alfa (PRX-110) Details
Genetic disorder, Rare genetic disease, Cystic fibrosis

Failed

Discontinued

OPRX-106 Details
Inflammatory disease, Bowel disorder

Failed

Discontinued